

ForPatients

by Roche

Leukemia Acute Graft Versus Host Disease

A study to look at the side effects of a study medicine (efmarodocokin alfa) in patients undergoing hematopoietic stem cell transplantation (HSCT)

Study to Evaluate the Safety and Pharmacokinetics of UTTR1147A in Combination With Standard of Care in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT04539470 GA41825

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This clinical trial was done to study a new medicine called, “efmarodocokin alfa,” for the treatment of patients with “graft versus host disease.” This study was done to find out if efmarodocokin alfa was safe enough to be given to patients undergoing hematopoietic stem cell transplantation. Side effects seen in this study were to be taken into consideration when determining if the doses tested could be tolerated. This was an open-label, Phase 1b, dose escalation study.

Genentech, Inc. (A part of F. Hoffmann-La Roche Ltd., Switzerland)
Sponsor

Phase 1b
Phase

NCT04539470 GA41825
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years

Healthy Volunteers
No
